---
title: "The first brain implant cleared to treat opioid addiction targets two brain regions at once"
date: 2026-11-12
category: Brain–Computer Interface
site: NeuroAI
canonical: https://neuroai.site/a/na-brain-sceneray-neurestora
language: en
---

# The first brain implant cleared to treat opioid addiction targets two brain regions at once

> Suzhou-based SceneRay won Chinese regulatory approval for Neurestora, a dual-target deep brain stimulation system for refractory opioid use disorder — the first such device cleared for addiction treatment.

For decades, doctors treating opioid addiction have worked with one hand tied. Medications blunt cravings, rehab rebuilds routine, yet relapse stays brutal and the underlying brain circuitry is left untouched.

A small implantable device approved in China in late 2025 takes a different bet: instead of asking the patient to outfight the urge, it tries to quiet the circuitry driving it.

The maker is not a household Silicon Valley name. It is SceneRay (景昱医疗), a Suzhou company that has spent more than a decade on a question most of the field passed over — could a brain implant actually help someone stay off opioids?

## Key takeaways

- SceneRay's Neurestora (植入式脑深部神经刺激系统) received China's NMPA Class III registration in December 2025 for refractory moderate-to-severe opioid use disorder (阿片类药物成瘾), as a relapse-prevention adjuvant therapy.

- It is a deep brain stimulation (DBS, 脑深部电刺激) system that stimulates two targets at once — the nucleus accumbens (伏隔核) and the anterior limb of the internal capsule (内囊前肢) — rather than the single target used in older DBS.

- The U.S. FDA granted the device Breakthrough Device designation; SceneRay says it is the first Chinese company to earn that status in a psychiatric indication.

- The company reports the platform has reached 300+ Parkinson's treatment centers in China and been exported to 18 countries, with 700+ patents filed.

## What the device actually does

Neurestora is an implantable deep brain stimulation system. Surgeons place a thin electrode — about one millimeter wide — through tiny burr holes in the skull, targeting precise structures deep in the brain, and tuck a roughly 25-gram pulse generator under the collarbone, linked by a subcutaneous lead. From there it delivers carefully tuned electrical pulses to reshape how two specific circuits fire.

The mechanism matters more than the hardware. Addiction is increasingly understood as a chronic, relapsing brain disorder, not a lapse of willpower. Conventional care — detox, medication-assisted treatment, rehab — can break physical dependence but often leaves the psychological drive to use untouched. The patient walks out of treatment clean, returns to the old neighborhood, sees the old cues, and the urge returns.

## Why two targets instead of one

Most DBS for movement disorders刺激 a single region. SceneRay's approach, which it calls dual-target (双靶点) DBS,刺激 two structures simultaneously through one electrode:

- The **nucleus accumbens (伏隔核)**, a hub of the brain's reward circuit. Stimulation here is aimed at easing the physical distress of withdrawal.

- The **anterior limb of the internal capsule (内囊前肢)**, tied to emotion regulation and impulse control. Stimulation here is aimed at fading the conditioned memories that make drug-related scenes feel unbearable to resist.

The company's argument is that addiction runs on two loops — a reward loop that drives the low-dopamine misery of withdrawal, and a memory loop that locks in cue-triggered craving. Hit both, the theory goes, and you attack the disease from both ends.

## The regulatory path and the Nature spotlight

China's National Medical Products Administration (国家药品监督管理局, NMPA) approved the implantable deep brain stimulator, electrode lead, and extension lead in December 2025, for refractory moderate-to-severe opioid use disorder as a relapse-prevention adjuvant. Chinese drug regulators described the system as filling a technical gap in physically intervening in opioid-addiction treatment.

The U.S. FDA had earlier granted the device Breakthrough Device designation. SceneRay says that makes it the first Chinese company to receive that status in a psychiatric indication. In June 2026, the company said *Nature* covered the work, an unusual move the company says reflected the completion of a full regulatory and clinical evidence chain rather than early-stage promise.

## A longer evidence chain than the hype cycle

This is not a overnight story. SceneRay was founded in Suzhou in 2011 by Ning Yihua (宁益华), a biomedical engineer who previously held roles at GE Healthcare, Medtronic, and Siemens. The dual-target hypothesis for addiction was proposed with Tangdu Hospital (唐都医院) in 2012 (per the company's published materials). The product entered China's special approval channel for innovative medical devices in 2017, received FDA Breakthrough status in 2018, and ran GCP clinical trials before the 2025 clearance.

The company's older Aaxon (脑起搏器) DBS line, approved in 2016 with an eight-contact product launched in 2024, already serves Parkinson's patients and forms the commercial base that funded the addiction program.

According to Li An, chief scientist at BrainNet (脑机网), China's neuromodulation edge may prove stronger in clinically anchored, regulatory-cleared therapies aimed at specific unmet needs than in headline implant races. Li An's comments reflect his own views and do not represent NeuroAI's editorial position or an endorsement by BrainNet (脑机网).

## What the numbers do — and don't — show

SceneRay reports long-term follow-up data from an ISAM (International Society of Addiction Medicine) congress in 2026, including a six-month abstinence rate around 80% and a seven-year stable-abstinence figure near 69%, with some patients able to stop stimulation and have the device removed after about two years. These figures come from the company's own presentations and have not been independently peer-reviewed in published form that we could locate. Treat them as the maker's claims, not settled clinical fact.

## Honest limitations

- The "world's first" framing for an addiction-cleared brain implant originates from Chinese regulators and the company; we did not independently reconcile it against every national medical-device registry worldwide.

- Efficacy percentages cited above are company-reported at a conference, not from a published, independently audited trial we could verify.

- We did not access the full NMPA submission dossier, the device's adverse-event profile, or long-term safety data; invasive brain stimulation carries surgical and stimulation-related risks that this article does not quantify.

- The piece focuses on one product and one company; it does not survey the broader competitive field of DBS for psychiatric use.

## What readers can do now

- If you or someone you know struggles with treatment-resistant opioid use disorder, ask a qualified addiction-medicine specialist whether neuromodulation is an appropriate, evidence-backed option in your region — and request published outcome data, not just marketing claims.

- Track the actual regulatory status: in China, verify the NMPA registration number and approved indication; outside China, check whether the device has any local approval before weighing it.

- Watch for peer-reviewed publications and independent trial registries; the strongest signal of real-world value will be reproduced, audited results rather than conference slides.

---

Published by NeuroAI (https://neuroai.site/) — https://neuroai.site/a/na-brain-sceneray-neurestora
Free to quote with attribution and a link to the original.
